A retrospective white paper released by ADAP Advocacy examines the 340B Drug Pricing Program, arguing that reform is necessary to realign the program with its original legislative intent. The paper, titled "340B Program: The Glue That Should Hold Our Healthcare System Together," contends that the program has prioritized provider interests over patient interests, leading to a lack of transparency and accountability.
Brandon M. Macsata, CEO of ADAP Advocacy, emphasized the need for broader transparency across the healthcare system, including the 340B Program. "There is an ongoing effort to push for greater transparency across multiple layers of this country's fragmented healthcare system, including hospitals' patient billing practices and pharmacy benefit managers' spread pricing policies. The 340B Program shouldn't be excluded from this broader effort, especially since the ultimate goal is improved program efficiency, leading to greater access to care and treatment for low-income patients," Macsata stated.
The white paper raises three central questions about the program's effectiveness: If 340B is designed to expand access and reduce financial burden, then why are patients increasingly unable to afford care? Why is 340B not adequately or even meaningfully addressing this problem? Why is it failing to meet the needs of the uninsured and the underinsured, the very persons it was designed to serve?
According to the paper, the 340B Program has grown to become the second-largest federal prescription drug program in the United States, behind Medicare Part D. However, its growth has outpaced the ability to clearly see how it is actually helping patients. "What started as a support mechanism has grown into something larger, both in terms of dollars and in the depth of the program's integration into the financial aspects of the American healthcare system. For that reason, a healthcare program of this size, magnitude, and importance cannot be entrusted to good faith alone; rather, improved accountability and transparency guardrails are needed to ensure its success and ultimately its intended beneficiaries: patients," the white paper reads.
The full white paper is available online at https://www.adapadvocacy.org/policycenter/340b. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration. The organization's mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS.
